Sweden-Based Cyxone, A Developer Of Therapies For Diseases Such As Rheumatoid Arthritis And Multiple Sclerosis As Well As Treatments For Virally Induced Acute Respiratory Disorders, Has Engaged A Major European Contract Development And Manufacturing Organization ( Cdmo ) For The Scale-Up And Production Of The Active Ingredient Of Its Drug Candidate T20K. The Production Will Be Performed In Accordance With Good Manufacturing Practice ( Gmp ), Exploring A Brand-New Manufacturing Method. The Collaboration Will Initially Cover Method Development And Later Supply Material For Use In Non-Clinical And Clinical Development Activities.Cyxone Is Developing T20K, A Peptide Aimed For The Treatment Of Multiple Sclerosis (Ms). Preclinical Data Indicate That The Drug Candidate Prevents Disease Progression In A Model System And Therefore Shows Potential To Slow Or Prevent Disease Progression Including Preventing The Demyelination Which Causes The Symptoms Of Ms.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!